Anokion_Logo_3-color_cs4 (002)


Event Partner

Anokion SA (including our wholly-owned subsidiaries Anokion US, Inc. and Kanyos Bio, Inc.) is clinical-stage biotechnology company focused on improving the treatment and outcomes of autoimmune disease. Our proprietary antigen-specific immune tolerance technology harnesses the liver’s natural tolerance pathway to modulate the harmful inflammatory immune response in antigen-mediated autoimmune diseases. Our engineered proteins are targeted to receptors on liver cells with the goal to educate our immune system to recognize the target antigens as self. Two product candidates are currently in clinical trials: KAN-101 in CeD patients (ACeD) and ANK-700 in RRMS patients (MoveS-it).